CSPC Group announced that the biopharmaceutical marketing application for the usinumab injection developed by the company's subsidiary Shiyao Group Jushi Biopharmaceutical Co., Ltd. has been officially accepted by the State Drug Administration of the People's Republic of China. This product is an all-human Ig G1monoclonal antibody which is an IL-12/IL-23p40 inhibitor and is indicated for plaque-like psoriasis in adults and children.

Zhitongcaijing · 11/26 09:09
CSPC Group announced that the biopharmaceutical marketing application for the usinumab injection developed by the company's subsidiary Shiyao Group Jushi Biopharmaceutical Co., Ltd. has been officially accepted by the State Drug Administration of the People's Republic of China. This product is an all-human Ig G1monoclonal antibody which is an IL-12/IL-23p40 inhibitor and is indicated for plaque-like psoriasis in adults and children.